Back to Journals » OncoTargets and Therapy » Volume 16

miR-497 Inhibited Proliferation, Migration and Invasion of Thyroid Papillary Carcinoma Cells by Negatively Regulating YAP1 Expression [Retraction]

Authors Cheng H, Dong H, Feng J, Tian H, Zhang H, Xu L

Received 17 January 2023

Accepted for publication 17 January 2023

Published 19 January 2023 Volume 2023:16 Pages 47—48


Cheng H, Dong H, Feng J, Tian H, Zhang H, Xu L. Onco Targets Ther. 2018;11:4711–4721.

At the authors request, the Editor and Publisher of OncoTargets and Therapy wish to retract the published article. Concerns were raised to the authors regarding the duplication of cell migration and invasion images in Figures 4 and 7. Specifically,

  • Figure 4C, miR-497 inhibitors, appears to have been duplicated with the same image for Figure 7D, Blank.
  • Figure 4C, miR-497 inhibitors and Figure 7D, Blank, both appear to have been duplicated with Figure 7D, miR-497 inhibitors, which has been flipped.

The authors were unable to provide a satisfactory explanation for the duplicated images, nor were they able to provide adequate original data that would verify the validity of the findings. The Editor agreed with the authors request to retract the article.

We have been informed in our decision-making by our policy on publishing ethics and integrity and the COPE guidelines on retractions.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.

This retraction relates to this paper

Creative Commons License © 2023 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.